Implantation of drug-eluting stents (DES) is the dominant treatment strategy for patients with symptomatic coronary artery disease. However, the first-generation DES had substantial drawbacks, including delayed healing, local hypersensitivity reactions and neoatherosclerosis, which all led to a steady increase in major adverse cardiovascular events over time. Subsequently, newer-generation DES were introduced with thinner struts, different scaffold designs (to improve deliverability while maintaining radial strength), different durable and biodegradable polymers — and in some cases no polymer (to improve vascular biocompatibility) — and new antiproliferative drug types and doses. Currently, >30 different DES are commercially available in Europe, with fewer available in the USA but with many new entrants coming onto the US market in the next few years. Never before have cardiologists been faced with so many choices of stent, each with its own unique design. In this Review, we detail preclinical and pathology studies for each stent design, examining thromboresistance, speed of neointimal coverage and completeness of healing, including endothelialization. We conclude by discussing how these design characteristics might affect the potential for shortening the minimum duration of dual antiplatelet therapy needed after coronary intervention.
Implantation of drug-eluting stents (DES) is the main treatment strategy for patients with coronary artery disease.
Stent design, stent material, strut thickness and vessel-wall coverage all influence clinical outcomes, and thin-strut DES are the standard.
Durable polymers, particularly fluoropolymers, are protective against thrombogenicity in the acute phase after stent implantation.
Endothelial barrier dysfunction after DES implantation is caused by mechanistic target of rapamycin inhibitors and might have an important role in the pathogenesis of neoatherosclerosis.
In experimental animal models, abluminally coated biodegradable-polymer DES and polymer-free DES allow earlier healing and faster return of endothelial barrier function than durable-polymer DES, owing to curtailed duration of drug residence in the arterial wall.
Thromboresistance might be important for reducing the mandatory duration of dual antiplatelet therapy and functional endothelialization might allow better long-term healing and prevent neoatherosclerosis.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Byrne, R. A., Stone, G. W., Ormiston, J. & Kastrati, A. Coronary balloon angioplasty, stents, and scaffolds. Lancet 390, 781–792 (2017).
Torrado, J. et al. Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis. J. Am. Coll. Cardiol. 71, 1676–1695 (2018).
Garg, S., Bourantas, C. & Serruys, P. W. New concepts in the design of drug-eluting coronary stents. Nat. Rev. Cardiol. 10, 248–260 (2013).
Palmerini, T. et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J. Am. Coll. Cardiol. 65, 2496–2507 (2015).
Foin, N. et al. Impact of stent strut design in metallic stents and biodegradable scaffolds. Int. J. Cardiol. 177, 800–808 (2014).
Foin, N. et al. Importance of knowing stent design threshold diameters and post-dilatation capacities to optimise stent selection and prevent stent overexpansion/incomplete apposition during PCI. Int. J. Cardiol. 166, 755–758 (2013).
Gomez-Lara, J. et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc. Interv. 3, 1190–1198 (2010).
Ormiston, J. A., Webber, B. & Webster, M. W. Stent longitudinal integrity bench insights into a clinical problem. JACC Cardiovasc. Interv. 4, 1310–1317 (2011).
Chichareon, P. et al. Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. Expert Rev. Med. Devices 16, 211–228 (2019).
Torii, S. et al. Comparison of in vivo longitudinal strength and conformability following stent implantation in rabbit iliac artery. J. Invasive Cardiol. 26, 64–69 (2014).
Barragan, P., Garitey, V., Mouneimne, K. & Rieu, R. Longitudinal compression behaviour of coronary stents: a bench-top comparative study. EuroIntervention 9, 1454–1462 (2014).
Sciahbasi, A. et al. Closed versus open cell stent for high-risk percutaneous coronary interventions in ST-elevation acute myocardial infarction: the Closed versus Open Cells stent for High risk percutaneous coronary Interventions in ST-Elevation acute myocardial infarction (COCHISE) pilot study. Am. Heart J. 165, 415–420 (2013).
Kastrati, A. et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103, 2816–2821 (2001).
Sakamoto, A., Jinnouchi, H., Torii, S., Virmani, R. & Finn, A. V. Understanding the impact of stent and scaffold material and strut design on coronary artery thrombosis from the basic and clinical points of view. Bioengineering 5, E71 (2018).
Kolandaivelu, K. et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123, 1400–1409 (2011).
Palmaz, J. C., Bailey, S., Marton, D. & Sprague, E. Influence of stent design and material composition on procedure outcome. J. Vasc. Surg. 36, 1031–1039 (2002).
Morlacchi, S. & Migliavacca, F. Modeling stented coronary arteries: where we are, where to go. Ann. Biomed. Eng. 41, 1428–1444 (2013).
Van der Heiden, K. et al. The effects of stenting on shear stress: relevance to endothelial injury and repair. Cardiovasc. Res. 99, 269–275 (2013).
Bangalore, S., Toklu, B., Patel, N., Feit, F. & Stone, G. W. Newer generation ultra-thin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease: a meta-analysis of randomized trials. Circulation 138, 2216–2226 (2018).
Virmani, R. et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109, 701–705 (2004).
Wilson, G. J. et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 120, 141–149 (2009).
Nakazawa, G. et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J. Am. Coll. Cardiol. 57, 390–398 (2011).
Nakazawa, G. et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J. Am. Coll. Cardiol. 57, 1314–1322 (2011).
Galloe, A. M. et al. 10-year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary stents. J. Am. Coll. Cardiol. 69, 616–624 (2017).
Hasebe, T. et al. Fluorine doping into diamond-like carbon coatings inhibits protein adsorption and platelet activation. J. Biomed. Mater. Res. A 83, 1192–1199 (2007).
Rogers, C. & Edelman, E. R. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 91, 2995–3001 (1995).
Price, M. J. et al. Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: primary outcome of the RESOLUTE ONYX core trial. Catheter. Cardiovasc. Interv. 92, 253–259 (2018).
Jensen, L. O. et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: 5-year results from SORT OUT IV. J. Am. Coll. Cardiol. 67, 751–762 (2016).
Otsuka, F. et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation 129, 211–223 (2014).
Otsuka, F. et al. Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography. Circulation 131, 322–324 (2015).
Torii, S., Virmani, R. & Finn, A. An uncommon but important cause of stent thrombosis: Kounis syndrome. Cardiovasc. Revasc. Med. 19, 818–819 (2018).
Kandzari, D. E. et al. Randomized comparison of ridaforolimus- and zotarolimus-eluting coronary stents in patients with coronary artery disease: primary results from the BIONICS trial (BioNIR ridaforolimus-eluting coronary stent system in coronary stenosis). Circulation 136, 1304–1314 (2017).
Yazdani, S. K. et al. Stent coating integrity of durable and biodegradable coated drug eluting stents. J. Interv. Cardiol. 29, 483–490 (2016).
Adriaenssens, T. et al. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation 136, 1007–1021 (2017).
Torii, S. et al. Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer free stents. EuroIntervention 14, 1685–1693 (2018).
Szott, L. M., Irvin, C. A., Trollsas, M., Hossainy, S. & Ratner, B. D. Blood compatibility assessment of polymers used in drug eluting stent coatings. Biointerphases 11, 029806 (2016).
Eppihimer, M. J. et al. Impact of stent surface on thrombogenicity and vascular healing: a comparative analysis of metallic and polymeric surfaces. Circ. Cardiovasc. Interv. 6, 370–377 (2013).
Sabate, M. et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 380, 1482–1490 (2012).
Otsuka, F. et al. Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. JACC Cardiovasc. Interv. 8, 1248–1260 (2015).
El-Hayek, G. et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc. Interv. 10, 462–473 (2017).
Meredith, I. T. et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J. Am. Coll. Cardiol. 59, 1362–1370 (2012).
Kandzari, D. E. et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet 390, 1843–1852 (2017).
Kufner, S. et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. Circulation 139, 325–333 (2019).
Busch, R. et al. New stent surface materials: the impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets. Acta Biomater. 10, 688–700 (2014).
Tada, N. et al. Polymer-free Biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ. Cardiovasc. Interv. 3, 174–183 (2010).
Mehilli, J. et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113, 273–279 (2006).
Joner, M. et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48, 193–202 (2006).
Finn, A. V. et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115, 2435–2441 (2007).
Gutierrez-Chico, J. L. et al. Delayed coverage in malapposed and side-branch struts with respect to well-apposed struts in drug-eluting stents: in vivo assessment with optical coherence tomography. Circulation 124, 612–623 (2011).
Nakamura, D. et al. Failure mechanisms and neoatherosclerosis patterns in very late drug-eluting and bare-metal stent thrombosis. Circ. Cardiovasc. Interv. 9, e003785 (2016).
Yazdani, S. K. et al. Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. J. Invasive Cardiol. 25, 383–390 (2013).
Torii, S. et al. Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries. Cardiovasc. Interv. Ther. 33, 55–61 (2016).
Nakazawa, G. et al. Comparison of vascular response between durable and biodegradable polymer-based drug-eluting stents in a porcine coronary artery model. EuroIntervention 10, 717–723 (2014).
Wilson, G. J. et al. The SYNERGY biodegradable polymer everolimus eluting coronary stent: porcine vascular compatibility and polymer safety study. Catheter. Cardiovasc. Interv. 86, E247–E257 (2015).
Nakazawa, G. et al. Comparison of vascular responses following new-generation biodegradable and durable polymer-based drug-eluting stent implantation in an atherosclerotic rabbit iliac artery model. J. Am. Heart Assoc. 5, e003803 (2016).
Jinnouchi, H. et al. Thromboresistance and functional healing in the COBRA PzF stent versus competitor DES: implications for dual anti-platelet therapy. EuroIntervention https://doi.org/10.4244/EIJ-D-18-00740 (2018).
Guagliumi, G. et al. Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. Eur. Heart J. 39, 2448–2456 (2018).
Kuramitsu, S. et al. Vascular response to bioresorbable polymer sirolimus-eluting stent versus permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial. Eur. Heart J. Cardiovasc. Imaging 17, 34–40 (2016).
Adriaenssens, T. et al. STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus versus biolimus A9-eluting stent implantation): a randomised controlled trial. EuroIntervention 11, e1619–e1626 (2016).
Nakano, M. et al. Additive value of integrated backscatter IVUS for detection of vulnerable plaque by optical frequency domain imaging: an ex vivo autopsy study of human coronary arteries. JACC Cardiovasc. Imaging 9, 163–172 (2016).
Fujii, K. et al. Accuracy of OCT, grayscale IVUS, and their combination for the diagnosis of coronary TCFA: an ex vivo validation study. JACC Cardiovasc. Imaging 8, 451–460 (2015).
Torii, S. et al. Simultaneous intravascular ultrasound usage overcomes misinterpretation when evaluating lipid-rich plaques with optical frequency domain imaging — ex vivo study. Circ. J. 79, 2641–2647 (2015).
Poulsen, C. B. et al. Plaque burden influences accurate classification of fibrous cap atheroma by in vivo optical coherence tomography in a porcine model of advanced coronary atherosclerosis. EuroIntervention 14, 1129–1135 (2018).
Habib, A. & Finn, A. V. Antiproliferative drugs for restenosis prevention. Interv. Cardiol. Clin. 5, 321–329 (2016).
Houghton, P. J. Everolimus. Clin. Cancer Res. 16, 1368–1372 (2010).
Puranik, A. S., Dawson, E. R. & Peppas, N. A. Recent advances in drug eluting stents. Int. J. Pharm. 441, 665–679 (2013).
Gupta, M. L. Jr., Bode, C. J., Georg, G. I. & Himes, R. H. Understanding tubulin-taxol interactions: mutations that impart taxol binding to yeast tubulin. Proc. Natl Acad. Sci. USA 100, 6394–6397 (2003).
Palmerini, T. et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 379, 1393–1402 (2012).
Torii, S. et al. Comparison of biologic effect and particulate embolization after femoral artery treatment with three drug-coated balloons in healthy swine model. J. Vasc. Interv. Radiol. 30, 103–109 (2019).
Torii, S. et al. Biologic drug effect and particulate embolization of drug-eluting stents versus drug-coated balloons in healthy swine femoropopliteal arteries. J. Vasc. Interv. Radiol. 29, 1041–1049 (2018).
Katsanos, K., Spiliopoulos, S., Kitrou, P., Krokidis, M. & Karnabatidis, D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 7, e011245 (2018).
Otsuka, F. et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur. Heart J. 36, 2147–2159 (2015).
Mori, H. et al. Very late pathological responses to cobalt-chromium everolimus-eluting, stainless steel sirolimus-eluting, and cobalt-chromium bare metal stents in humans. J. Am. Heart Assoc. 6, e007244 (2017).
Jinnouchi, H. et al. Difference of tissue characteristics between early and late restenosis after second-generation drug-eluting stents implantation- an optical coherence tomography study. Circ. J. 81, 450–457 (2017).
Taniwaki, M. et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation 133, 650–660 (2016).
Lee, S. Y. et al. Characteristics of earlier versus delayed presentation of very late drug-eluting stent thrombosis: an optical coherence tomographic study. J. Am. Heart Assoc. 6, e005386 (2017).
Kuroda, M. et al. The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. EuroIntervention 12, e1366–e1374 (2016).
Habib, A. et al. Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-alpha activation and disruption of the p120-vascular endothelial cadherin interaction. Arterioscler. Thromb. Vasc. Biol. 33, 2425–2431 (2013).
Watanabe, M. et al. The pleiotropic regulation of cyclin D1 by newly identified sesaminol-binding protein ANT2. Oncogenesis 6, e311 (2017).
Harari, E. et al. Direct targeting of the mTOR (mammalian target of rapamycin) kinase improves endothelial permeability in drug-eluting stents — brief report. Arterioscler. Thromb. Vasc. Biol. 38, 2217–2224 (2018).
Mori, H. et al. Endothelial barrier protein expression in biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting metallic stents. JACC Cardiovasc. Interv. 10, 2375–2387 (2017).
Mridha, N. et al. A meta-analysis of randomised-controlled trials to compare long-term clinical outcomes of bioabsorbable-polymer and durable-polymer drug-eluting stents. Eur. Heart J. Qual. Care Clin. Outcomes 5, 105–113 (2018).
Huynh, K. Antiplatelet therapy: risks and benefits of extended DAPT after stenting. Nat. Rev. Cardiol. 12, 1 (2015).
Gori, T. et al. Predictors of stent thrombosis and their implications for clinical practice. Nat. Rev. Cardiol. 16, 243–256 (2018).
Palmerini, T. et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur. Heart J. 38, 1034–1043 (2017).
Navarese, E. P. et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 350, h1618 (2015).
Valgimigli, M. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 39, 213–260 (2017).
Urban, P. et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N. Engl. J. Med. 373, 2038–2047 (2015).
Mauri, L. et al. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. Am. Heart J. 205, 110–117 (2018).
Colombo, A., Giannini, F. & Briguori, C. Should we still have bare-metal stents available in our catheterization laboratory? J. Am. Coll. Cardiol. 70, 607–619 (2017).
Krucoff, M. W. LEADERS FREE II: evaluation of a polymer-free coronary drug-eluting stent in high bleeding-risk patients with one-month dual antiplatelet therapy [abstract]. Presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2018).
Varenne, O. et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet 391, 41–50 (2018).
Vranckx, P. et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392, 940–949 (2018).
S.T. receives research grants from SUNRISE lab. A.C. receives research grants from University Hospital RWTH Aachen. R.V. and A.V.F. have received institutional research support from 480 Biomedical, 4C Medical, 4Tech, Abbott, Accumedical, Amgen, Bard, Biosensors, Boston Scientific, Cardiac Implants, Celonova, Claret Medical, Concept Medical, Cook, CSI, DuNing, Edwards LifeSciences, Emboline, Endotronix, Envision Scientific, Gateway, Leducq Foundation Grant (R01 HL141425), Lifetech, Limflo, MedAlliance, Medtronic, Mercator, Merill, Microport Medical, Microvention, Mitraalign, Mitra assist, NAMSA, Nanova, Neovasc, NIPRO, Novogate, Occulotech, OrbusNeich Medical, Phenox, Profusa, Protembis, Qool, Recor, Senseonics, Shockwave, Sinomed, Spectranetics, Surmodics, Symic, Vesper, W.L. Gore and Xeltis. R.V. has received honoraria from Abbott Vascular, Biosensors, Boston Scientific, Celonova, Cook Medical, Cordis, CSI, Lutonix Bard, Medtronic, OrbusNeich Medical, CeloNova, SINO Medical Technology, ReCore, Spectranetics, Terumo Corporation and W. L. Gore. R.V. is a consultant for Abbott Vascular, Boston Scientific, Celonova, Cook Medical, Cordis, CSI, Edwards Lifescience, Lutonix Bard, Medtronic, OrbusNeich Medical, ReCore, Sinomededical Technology, Spectranetics, Surmodics, Terumo Corporation, W. L. Gore and Xeltis. A.V.F. has received honoraria from Abbott Vascular, Biosensors, Boston Scientific, Celonova, Cook Medical, CSI, Lutonix Bard, Sinomed and Terumo Corporation. A.V.F. is a consultant for Amgen, Abbott Vascular, Boston Scientific, Celonova, Cook Medical, Lutonix Bard and Sinomed. The other authors declare no competing interests.
Peer review information
Nature Reviews Cardiology thanks A. Kastrati, P. Serruys and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Torii, S., Jinnouchi, H., Sakamoto, A. et al. Drug-eluting coronary stents: insights from preclinical and pathology studies. Nat Rev Cardiol 17, 37–51 (2020). https://doi.org/10.1038/s41569-019-0234-x
Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients
Scientific Reports (2021)
Design, Development, In Vitro and Preliminary In Vivo Evaluation of a Novel Photo-Angioplasty Device: Lumi-Solve
Cardiovascular Engineering and Technology (2021)